Omeros Co. (NASDAQ:OMER) reached a new 52-week high on Tuesday . The company traded as high as $27.00 and last traded at $26.55, with a volume of 16235 shares traded. The stock had previously closed at $26.28.

OMER has been the subject of a number of research reports. Wedbush set a $20.00 target price on Omeros and gave the stock a “hold” rating in a report on Friday, August 10th. Zacks Investment Research raised Omeros from a “sell” rating to a “hold” rating in a report on Saturday, August 18th. HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Omeros in a report on Thursday, June 28th. ValuEngine raised Omeros from a “hold” rating to a “buy” rating in a research note on Friday, July 6th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $32.00 price target on shares of Omeros in a research note on Tuesday, August 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $27.56.

The company has a market cap of $1.22 billion, a P/E ratio of -33.92 and a beta of 3.84. The company has a debt-to-equity ratio of -2.31, a current ratio of 3.95 and a quick ratio of 3.94.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.04). The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $1.84 million. The firm’s quarterly revenue was down 90.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.33) earnings per share. equities research analysts predict that Omeros Co. will post -2.48 earnings per share for the current fiscal year.

In other Omeros news, VP Marcia S. Kelbon sold 40,723 shares of Omeros stock in a transaction dated Friday, July 27th. The stock was sold at an average price of $21.56, for a total value of $877,987.88. Following the transaction, the vice president now owns 219,645 shares in the company, valued at $4,735,546.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Marcia S. Kelbon sold 7,529 shares of Omeros stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $25.75, for a total value of $193,871.75. Following the completion of the transaction, the vice president now owns 227,645 shares in the company, valued at approximately $5,861,858.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 52,529 shares of company stock valued at $1,163,730. 12.10% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. BlueMountain Capital Management LLC bought a new position in Omeros in the second quarter valued at about $118,000. Quad Cities Investment Group LLC bought a new position in Omeros in the second quarter valued at about $161,000. Belpointe Asset Management LLC bought a new position in Omeros in the second quarter valued at about $204,000. Claraphi Advisory Network LLC bought a new position in Omeros in the first quarter valued at about $134,000. Finally, Cubist Systematic Strategies LLC bought a new position in Omeros in the second quarter valued at about $274,000. Hedge funds and other institutional investors own 48.11% of the company’s stock.

Omeros Company Profile (NASDAQ:OMER)

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: What is the NASDAQ?

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.